KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Cash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Change in Receivables (2016 - 2022)

Historic Change in Receivables for TherapeuticsMD (TXMD) over the last 13 years, with Q3 2022 value amounting to -$13.6 million.

  • TherapeuticsMD's Change in Receivables fell 43981.57% to -$13.6 million in Q3 2022 from the same period last year, while for Sep 2022 it was -$4.3 million, marking a year-over-year decrease of 13018.77%. This contributed to the annual value of $4.3 million for FY2021, which is 4738.57% down from last year.
  • Latest data reveals that TherapeuticsMD reported Change in Receivables of -$13.6 million as of Q3 2022, which was down 43981.57% from $11.1 million recorded in Q2 2022.
  • Over the past 5 years, TherapeuticsMD's Change in Receivables peaked at $11.1 million during Q2 2022, and registered a low of -$13.6 million during Q3 2022.
  • Its 5-year average for Change in Receivables is $1.6 million, with a median of $790885.0 in 2018.
  • As far as peak fluctuations go, TherapeuticsMD's Change in Receivables crashed by 276732.05% in 2018, and later surged by 4832608.7% in 2022.
  • Over the past 5 years, TherapeuticsMD's Change in Receivables (Quarter) stood at -$1.8 million in 2018, then skyrocketed by 629.91% to $9.3 million in 2019, then decreased by 7.4% to $8.6 million in 2020, then tumbled by 114.32% to -$1.2 million in 2021, then tumbled by 1006.81% to -$13.6 million in 2022.
  • Its Change in Receivables stands at -$13.6 million for Q3 2022, versus $11.1 million for Q2 2022 and -$489000.0 for Q1 2022.